Free Diffuse Large B-cell Lymphoma Prognosis Calculator

Understanding DLBCL Prognosis with the Revised IPI Score

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma originating from white blood cells called lymphocytes. Unlike leukemia, DLBCL frequently forms solid tumors, most often in lymph nodes, the spleen, or the thymus, and it can spread rapidly throughout the body. Accurate prognosis assessment is vital for guiding treatment decisions. The DLBCL Prognosis Calculator utilizes the Revised International Prognostic Index (R-IPI) to estimate both overall survival and progression-free survival, providing a personalized DLBCL risk assessment based on five key clinical factors.

Key Signs and Symptoms of DLBCL

Lymphomas may be asymptomatic for extended periods, but many patients eventually develop B symptoms:

• Persistent fatigue
• Night sweats
• Unintentional weight loss
• Unexplained fever

Acute complications can arise suddenly, such as superior vena cava syndrome (swelling and flushing of the upper body due to blocked venous return) or severe shortness of breath caused by enlarged lymph nodes compressing the airways. These emergencies can occur at any disease stage, not only in advanced DLBCL.

Ann Arbor Staging and Its Modifiers

The disease stage is a critical element of the revised IPI score. The Ann Arbor system classifies DLBCL into four stages:

• Stage I: A single lymph node region or a single extralymphatic organ is involved.
• Stage II: Two or more lymph node regions on the same side of the diaphragm are affected.
• Stage III: Lymph node groups are involved on both sides of the diaphragm.
• Stage IV: Diffuse involvement of one or more distant extralymphatic organs (e.g., liver, lungs, kidneys, central nervous system).

Modifiers add precision:

• A/B: Absence or presence of B symptoms.
• S: Spleen involvement.
• E: Extranodal disease (outside lymph nodes).
• X: Bulky disease (largest mass >10 cm or mediastinal mass >1/3 chest width on X-ray).

How the Revised IPI Score Is Calculated

The original IPI was updated to the R-IPI after rituximab became part of standard therapy, yielding a more accurate Non-Hodgkin lymphoma prognosis for modern treatments. The score sums one point for each of the following risk factors present:

Risk Factor	Points (if Yes)
Age >60 years	1
Stage III or IV	1
Elevated serum LDH	1
ECOG performance status 2–4	1
More than one extranodal site	1

The total ranges from 0 to 5; a higher score indicates a worse predicted outcome.

Age‑Adjusted IPI: For patients within the same age cohort, an adjusted version considers only three factors (stage III/IV, elevated LDH, and ECOG 2–4), omitting age and extranodal site count. This enables comparison of prognosis among individuals of similar age.

Using the Lymphoma Survival Calculator

To obtain a prognosis estimate, simply indicate whether each R-IPI factor applies. The calculator sums the points and generates a projected survival curve (overall and progression‑free) based on published R-IPI data. This lymphoma survival calculator supports clinicians and patients in evaluating treatment intensity and planning follow‑up.

It is important to remember that the tool provides a statistical estimate, not a guaranteed outcome. Individual responses to therapy vary, and all results should be discussed with a qualified healthcare provider.